Idecabtagene vicleucel at a glance
Medicine class
BCMA-directed, genetically modified autologous CAR T-cell therapy.
Main use
Relapsed and refractory multiple myeloma in eligible adults after specified previous therapies.
Administration
A patient-specific intravenous infusion given in a qualified specialist treatment centre.
After treatment
Close monitoring is required; patients should remain near the treatment centre for at least two weeks and carry their patient alert card.
What is Idecabtagene vicleucel used for?
UK-licensed use:
Adults with relapsed and refractory multiple myeloma who have received at least two previous therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose disease progressed on their latest therapy.
How does Idecabtagene vicleucel work?
The patient’s T cells are modified to carry a chimeric antigen receptor that recognises BCMA, a protein found on myeloma cells and normal plasma cells. Binding to BCMA activates and expands the modified T cells, enabling them to kill BCMA-expressing cells.
How to take Idecabtagene vicleucel
T cells are collected from the patient and sent for personalised manufacture. Preparative chemotherapy is given before idecabtagene vicleucel, which is infused into a vein at a qualified centre after identity checks.
Follow the treatment centre’s instructions for appointments and monitoring.
Carry the patient alert card and show it whenever receiving medical care.
Remain near the treatment centre for at least two weeks after infusion.
Do not donate blood, organs, tissues or cells for transplantation.
Avoid driving, machinery and activities requiring alertness until the specialist team says it is safe.
Idecabtagene vicleucel side effects
Common or expected effects
- Cytokine release syndrome, often causing fever, chills, low blood pressure or a fast heartbeat
- Low white cells, red cells or platelets
- Infections
- Diarrhoea, nausea, vomiting or constipation
- Fatigue
- Headache or dizziness
- Low blood levels of phosphate, potassium, calcium or magnesium
- Reduced immunoglobulin levels
- Joint pain or swelling
Get urgent medical advice
- Cytokine release syndrome
- Neurological toxicity, including confusion, sleepiness, speech or memory problems, poor coordination, weakness or seizures
- Severe infection
- Bleeding, bruising, profound weakness or breathlessness associated with low blood counts
- New lymph-node swelling, skin lumps or persistent unexplained symptoms that could indicate a secondary cancer
Idecabtagene vicleucel in pregnancy
There are no adequate pregnancy data, and harm to the fetus is possible if modified cells cross the placenta. Pregnancy testing is required before treatment; use during pregnancy or without contraception is not recommended. Discuss pregnancy after treatment promptly with the specialist team.
Idecabtagene vicleucel while breastfeeding
It is unknown whether the modified cells enter breast milk or could affect a breastfed child, and risk cannot be excluded. Discuss breastfeeding with the specialist team before treatment or after exposure.
Idecabtagene vicleucel interactions
Formal interaction studies are limited. Tell the specialist team about all prescribed, non-prescribed and complementary products.
Corticosteroids and other medicines that inhibit T-cell function
They may interfere with CAR T-cell activity, although specialists may need corticosteroids to manage serious toxicity.
Medicines that stimulate T-cell function
Combined effects have not been studied and are unknown.
Live viral vaccines
They are not recommended before preparative chemotherapy, during treatment or until immune recovery because safety has not been established.
Common questions about Idecabtagene vicleucel
Answers are fully visible for fast scanning and source review.
Is idecabtagene vicleucel chemotherapy?
No. It is personalised CAR T-cell therapy made from the patient’s own immune cells, although preparative chemotherapy is given beforehand.
Why is it only given at specialist centres?
It can cause rapidly developing cytokine release syndrome, neurological toxicity and other serious complications requiring trained staff, close monitoring and emergency treatment.
Can side effects start late?
Yes. Important reactions usually occur early but may develop later. Promptly report new fever, neurological symptoms, signs of infection or unexplained lumps.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.